Cynata Therapeutics Takes Fresh Approach to Stem Cell Production


Ross Macdonald, PhD, managing director and CEO of Cynata Therapeutics, discusses the biotech company's approach to overcoming reproducibility challenges with mesenchymal stem cells.

Much like the manufacturing challenges that plague the gene therapy space, biotechnology companies focused on stem cell and regenerative therapies often find themselves faced with reproducibility issues that can compromise the quality of the end product.

Derived from donated tissue, current industry-standard manufacturing processes that rely upon cell reproduction within cell cultures are self-limiting.

"Excessive culture, prior to utilization as a therapy in therapeutic purposes, causes the cells to undergo what's called senescence, and they are no longer as potent or as efficient as they were when they were freshly isolated," said Ross Macdonald, PhD, managing director and chief executive officer, Cynata Therapeutics.

To surpass these limitations, Macdonald and the Cynata team have developed a novel manufacturing platform, called Cymerus, that utilizes mesenchymoangioblasts derived from induced pluripotent stem cells.

In an interview with GeneTherapyLive, Macdonald expanded on the advantages of the Cymerus platform and why their novel process can address several limitations of current industry standards.

Related Videos
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Related Content
© 2024 MJH Life Sciences

All rights reserved.